glp 1 agonist or antagonist A Closer Look at the Dermatological Profile of GLP-1 Agonists Frontiers | The agony and

In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [89]

Thieu, A

With respect to sex, the hazard ratio was lower among men (0.74, 95% CI 0.54 to 1.01) than women (1.10, 0.82 to 1.48), but with overlapping confidence intervals

Given the multiple pathophysiologic targets that exist in the setting of T2DM, it is common to encounter patients who require the use of multiple antihyperglycemic agents to successfully reach treatment goals

Each step roughly doubles the previous dose rather than adding a fixed increment